ASP CA00444G1081

Report

Delayed Toronto Stock Exchange - 04/22 02:51:39 pm
0.05	CAD		--.--%

04/01

ACERUS PHARMACEUTICALS : Buys Back All Remaining U.S. Rights for NATESTO From Aytu BioPharma

04/01

AYTU BIOPHARMA : Sells US Rights to Low Testosterone Treatment Natesto to Acerus Pharma

04/01

Acerus Buys Back All Remaining U.S. Rights for NATESTO® From Aytu

Summary

Quotes 5-day view Delayed Quote.

Delayed Toronto Stock Exchange

04/16/2021	04/19/2021	04/20/2021	04/21/2021	04/22/2021	Date
0.055(c)	0.05(c)	0.055(c)	0.05(c)	0.05(c)	Last
51 100	5 700	184 000	28 020	29 050	Volume
+10.00%	-9.09%	+10.00%	-9.09%	0.00%	Change

More quotes

Financials (USD)

Sales 2019	3,77 M - -
Net income 2019	-16,1 M - -
Net Debt 2019	14,7 M - -
P/E ratio 2019	-0,97x
Yield 2019	-

Sales 2020	1,09 M - -
Net income 2020	-24,4 M - -
Net cash position 2020	0,91 M - -
P/E ratio 2020	-1,05x
Yield 2020	-

Capitalization	61,5 M 61,5 M -
EV / Sales 2019	8,18x
EV / Sales 2020	43,7x
Nbr of Employees	10
Free-Float	8,36%

More Financials

Company

Acerus Pharmaceuticals Corporation, formerly Trimel Pharmaceuticals Corporation, is a Canada-based pharmaceutical company. The Company is engaged in the development, manufacture, marketing and distribution of products with a focus on men's health, including urology, and women's health, including hormone replacement therapy and female sexual dysfunction. The Company markets Estrace in Canada, which is an oral,...

Sector

Pharmaceuticals

Calendar

05/17

Earnings Release

More about the company

All news about ACERUS PHARMACEUTICALS CORPORATION

04/01	ACERUS PHARMACEUTICALS : Buys Back All Remaining U.S. Rights for NATESTO From A..	MT
04/01	AYTU BIOPHARMA : Sells US Rights to Low Testosterone Treatment Natesto to Aceru..	MT
04/01	Acerus Buys Back All Remaining U.S. Rights for NATESTO® From Aytu	GL
03/30	UPDATE : Acerus Pharmaceuticals Jumps 10% as Expands NATESTO Distribution to 20 ..	MT
03/30	ACERUS PHARMACEUTICALS : Expands NATESTO Distribution to 20 Countries	MT
03/30	Acerus Announces Expansion of NATESTO® Distribution Worldwide	GL
03/26	ACERUS PHARMACEUTICALS : Amends Credit Agreement	MT
03/26	Acerus Announces Amendment to Credit Agreement	GL
03/11	Acerus Pharmaceuticals Reports Q4 Loss Per Share US$0.01	MT
03/11	Acerus Reports Fourth Quarter and Full Year 2020 Financial Results	GL
03/11	ACERUS : Q4 Earnings Snapshot	AQ
03/04	ACERUS PHARMACEUTICALS : to Report 2020 Financial Results and Host Investor Cal..	AQ
2020	ACERUS PHARMACEUTICALS : Near 52 Week Lows Announces Waiver of Q4 Financial Cov..	MT
2020	ACERUS PHARMACEUTICALS : Raises C$13.2 Million as It Wraps Up Rights Offering	MT
2020	ACERUS PHARMACEUTICALS : Announces Details of Previously Completed Rights Offer..	BU

More news

News in other languages on ACERUS PHARMACEUTICALS CORPORATION

- No features available -

More news

Provided by Scoopnest.com

Chart ACERUS PHARMACEUTICALS CORPORATION

Duration : Period :

Acerus Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends ACERUS PHARMACEUTICALS CORPORATION

	Short Term	Mid-Term	Long Term
Trends	Bearish	Bullish	Bullish

Technical analysis

Income Statement Evolution

More Financials

Managers and Directors

Name	Title
Edward Gudaitis	President, CEO & Non-Independent Director
Robert M. Motz	Chief Financial Officer
Ian Orest Ihnatowycz	Chairman
Christopher Sorli	Chief Medical Officer
Stephen Gregory	Lead Independent Director

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

ACERUS PHARMACEUTICALS CORPORATION	25.00%	62



JOHNSON & JOHNSON	4.96%	438 583
ROCHE HOLDING AG	2.64%	298 619
PFIZER, INC.	7.39%	217 716
NOVARTIS AG	-2.89%	199 956
MERCK & CO., INC.	-4.69%	198 884

More Results